Abstract
Positron emission tomography (PET) and PET/computed tomography (PET/CT) with different tracers have been increasingly used in patients with thyroid tumours. The aim of this article is to perform an overview based on literature data about the usefulness of PET imaging in this setting. The role of Fluorine-18-Fluorodeoxyglucose (FDG) PET and PET/CT in differentiated thyroid carcinoma (DTC) is well established, particularly in patients presenting with elevated serum thyroglobulin levels and negative radioiodine whole-body scan. Iodine-124 PET and PET/CT may serve a role in staging DTC and obtaining lesional dosimetry for a better and more rationale planning of treatment with Iodine-131. FDG-PET and PET/CT are useful in the post-thyroidectomy staging of high-risk patients with less differentiated histological subtypes. PET and PET/CT with different tracers seem to be useful methods in localizing the source of elevated calcitonin levels in patients with recurrent medullary thyroid carcinoma. Incorporation of FDG-PET or PET/CT into the initial workup of patients with indeterminate thyroid nodules at fine needle aspiration biopsy deserves further investigation. FDG-PET report should suggest further evaluation when focal thyroid incidentalomas are described because these findings are associated with a significant risk of cancer.
Similar content being viewed by others
References
Treglia G, Cason E, Fagioli G (2010) Recent applications of nuclear medicine in diagnostics (first part). Ital J Med 4:84–91
Abraham T, Schöder H (2011) Thyroid cancer–indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 41:121–138
Giovanella L (2012) Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Expert Rev Endocrinol Metab 7:35–43
Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W (1995) 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34:127–134
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Dong MJ, Liu ZF, Zhao K et al (2009) Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 30:639–650
Ma C, Xie J, Lou Y, Gao Y, Zuo S, Wang X (2010) The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol 163:177–183
Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA (2012) Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck 34:626–631
Robbins RJ, Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505
Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ (2011) Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 38(Suppl 1):S48–S56
Freudenberg LS, Antoch G, Frilling A et al (2008) Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 35:950–957
Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY (2012) Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 37:121–127
Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW (2006) Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 47:1260–1266
Poisson T, Deandreis D, Leboulleux S et al (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37:2277–2285
American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612
Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L (2012) PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging 2012:324686
Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D (2008) Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 33:67–73
Treglia G, Villani MF, Giordano A, Rufini V (2012) Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. doi:10.1007/s12020-012-9671-6
Treglia G, Cocciolillo F, Di Nardo F et al (2012) Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol 19:1290–1299
Treglia G, Castaldi P, Villani MF et al (2012) Comparison of 18F-DOPA, 18F-FDG and 68 Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 39:569–580
Conry BG, Papathanasiou ND, Prakash V et al (2010) Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:49–57
Naswa N, Sharma P, Suman S et al (2012) Prospective evaluation of 68 Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun 33:766–774
Treglia G, Rindi G, Rufini V (2012) Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. Hormones 11:230–232
Treglia G, Castaldi P, Villani MF et al (2012) Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature. Recent Results Cancer Res 194:385–393
Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF (2011) The role of [(18) F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer 117:4582–4594
Deandreis D, Al Ghuzlan A, Auperin A et al (2012) Is (18)f-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 22:165–172
Giovanella L, Suriano S, Maffioli M, Ceriani L (2011) 18FDG-positron emission tomography/computed tomography (PET/CT) scanning in thyroid nodules with nondiagnostic cytology. Clin Endocrinol 74:644–648
Jin J, McHenry CR (2012) Thyroid incidentaloma. Best Pract Res Clin Endocrinol Metab 26:83–96
Iyer NG, Shaha AR, Silver CE et al (2010) Thyroid incidentalomas: to treat or not to treat. Eur Arch Otorhinolaryngol 267:1019–1026
Bonabi S, Schmidt F, Broglie MA, Haile SR, Stoeckli SJ (2012) Thyroid incidentalomas in FDG-PET/CT: prevalence and clinical impact. Eur Arch Otorhinolaryngol. doi:10.1007/s00405-012-1941-7
Rothman IN, Middleton L, Stack BC Jr, Bartel T, Riggs AT, Bodenner DL (2011) Incidence of diffuse FDG uptake in the thyroid of patients with hypothyroidism. Eur Arch Otorhinolaryngol 268:1501–1504
Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L (2012) Risk of malignancy in thyroid incidentalomas detected by (18)f-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 22:918–925
Bertagna F, Treglia G, Piccardo A, Giubbini R (2012) Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. doi:10.1210/jc.2012-2390
Treglia G, Giovanella L, Bertagna F, Di Franco D, Salvatori M (2012) A pooled analysis to calculate the prevalence and risk of malignancy of thyroid incidentalomas detected by Fluorine-18-Fluorodeoxyglucose positron emission tomography. Thyroid. doi:10.1089/thy.2012-0216
Conflict of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Treglia, G., Muoio, B., Giovanella, L. et al. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol 270, 1783–1787 (2013). https://doi.org/10.1007/s00405-012-2205-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-012-2205-2